Loading
NF1 makes neurofibromin, the protein that switches RAS off. People born with one faulty copy develop neurofibromatosis type 1, whose plexiform neurofibromas are now treated with the MEK inhibitors selumetinib and mirdametinib, which cut the RAS signal one step down. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
A tumour suppressor with no drug of its own: therapy targets the pathway it normally restrains. The two approved drugs are recorded with response rates in the corpus (two-thirds of 50 children in SPRINT stratum 1; 41% in ReNeu), and the MEK record notes that MEK inhibitors are selected on upstream BRAF, NF1 or RAS status rather than on MEK itself.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | 8-12% | Inactivating mutation | cBioPortal: 206 of 2,653, 7.8%, in luad_mskcc_2023_met_organotropism; 67 of 915, 7.3%, in lung_msk_2017; 66 of 566, 11.7%, in luad_tcga_pan_can_atlas_2018; 27 of 230, 11.7%, in luad_tcga_pub; 25 of 240, 10.4%, in nsclc_pd1_msk_2018; 10 of 302, 3.3%, in luad_oncosg_2020. | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"NF1" OR ABSTRACT:"NF1" OR TITLE:"neurofibromin" OR ABSTRACT:"neurofibromin" OR TITLE:"neurofibromin 1" OR ABSTRACT:"neurofibromin 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NF1 (neurofibromin), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/nf1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/nf1.json. Licence CC BY-NC 4.0.